Surveillance report describes 2019 cases of coccidioidomycosis, histoplasmosis, and blastomycosis in the US

A surveillance summary from the United States describes cases of three endemic fungal diseases—coccidioidomycosis, histoplasmosis, and blastomycosis—reported in 2019. The report provides a descriptive overview of these cases across the national population. No specific case counts, demographic breakdowns, geographic distributions, or comparative data from other years are reported in the provided information.

No intervention, exposure, comparator, or treatment data are included in this surveillance summary. The report focuses solely on case description for the specified year. Safety, tolerability, and adverse event data are not reported, as this is not a clinical trial but a public health surveillance document.

Key limitations include the absence of quantitative case numbers, making it impossible to assess the magnitude or trends of these diseases from this summary alone. The lack of comparator data (e.g., previous years) prevents any analysis of changes in incidence. The report's practice relevance is limited to providing a basic, non-quantitative awareness of ongoing endemic fungal disease surveillance in the US for 2019. Clinicians should seek more detailed epidemiological reports for specific case counts, risk factors, and trend analyses.